CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $35.04M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -0.84: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
366.61MUSDvs all stocks (USD)
Revenue (TTM)
35.04MUSDvs all stocks (USD)
Profit Margin
-289.44%vs Biotechnology peers
Beta
2.94xvs all stocks
52-Week Change
33.63%vs all stocks
Market Capitalization
366.61MUSDvs all stocks (USD)
Enterprise Value
169.81MUSDvs all stocks (USD)
Forward P/E
-2.99xvs Biotechnology peers
Price to Sales (TTM)
10.46xvs Biotechnology peers
Price to Book (MRQ)
1.48xvs Biotechnology peers
Enterprise to Revenue
4.85xvs Biotechnology peers
Enterprise to EBITDA
-1.71xvs Biotechnology peers
Profit Margin
-289.44%vs Biotechnology peers
Operating Margin
-397.88%vs Biotechnology peers
Return on Assets (TTM)
-19.25%vs Biotechnology peers
Return on Equity (TTM)
-48.14%vs Biotechnology peers
Revenue (TTM)
35.04MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.3140USDUpdated Sep 27, 2026Quarterly Revenue Growth
2.80%vs Biotechnology peers
Gross Profit (TTM)
30.25MUSDvs all stocks (USD)
EBITDA (TTM)
-99.45MUSDvs all stocks (USD)
Net Income (TTM)
-101.42MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
2.75%vs Biotechnology peers
Operating Cash Flow (TTM)
-84.87MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-43.66MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
35.95MUSDFY2025 · Dec 31, 2025Operating Income
-104.49MUSDvs all stocks (USD)
Pre-tax Income
-104.87MUSDFY2025 · Dec 31, 2025Income Tax Expense
121.00KUSDFY2025 · Dec 31, 2025Net Income
-104.99MUSDFY2025 · Dec 31, 2025EBIT
-104.49MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-91.80MUSDFY2025 · Dec 31, 2025Research & Development
104.24MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
36.20MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
10.35MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.27USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.27USDFY2025 · Dec 31, 2025Basic Shares Outstanding
82.89MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
82.89MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-104.99MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-108.21MUSDFY2025 · Dec 31, 2025Free Cash Flow
-108.82MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
78.05MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-104.99MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.96MUSDFY2025 · Dec 31, 2025Stock-based Compensation
19.10MUSDFY2025 · Dec 31, 2025Other Non-cash Items
99.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
701.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-468.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-24.61MUSDFY2025 · Dec 31, 2025Capital Expenditures
-607.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-227.07MUSDFY2025 · Dec 31, 2025Sale of Investments
219.08MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-8.60MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-193.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
274.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
126.29MUSDFY2025 · Dec 31, 2025Shares Outstanding
122.91MSharesUpdated Sep 27, 2026Float Shares
94.51MSharesUpdated Sep 27, 2026Shares Short
40.19MSharesUpdated Sep 27, 2026Short Ratio
19.76daysvs all stocks
Short % of Shares Outstanding
32.86%vs all stocks
% Held by Insiders
0.84%vs all stocks
% Held by Institutions
103.10%vs all stocks
Total Cash (MRQ)
253.66MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.06USDUpdated Sep 27, 2026Total Debt (MRQ)
56.86MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2299xvs Biotechnology peers
Current Ratio (MRQ)
5.45xvs Biotechnology peers
Book Value per Share (MRQ)
2.01USDUpdated Sep 27, 2026Total Assets
359.07MUSDvs all stocks (USD)
Total Current Assets
258.11MUSDFY2025 · Dec 31, 2025Total Liabilities
102.49MUSDFY2025 · Dec 31, 2025Total Non-current Assets
100.97MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
69.46MUSDFY2025 · Dec 31, 2025Total Current Liabilities
33.03MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
74.60MUSDFY2025 · Dec 31, 2025Other Short-term Investments
173.93MUSDFY2025 · Dec 31, 2025Accounts Receivable
2.40MUSDFY2025 · Dec 31, 2025Accounts Payable
858.00KUSDFY2025 · Dec 31, 2025Short-term Debt
6.37MUSDFY2025 · Dec 31, 2025Deferred Revenue
12.49MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.40MUSDFY2025 · Dec 31, 2025Long-term Debt
53.62MUSDFY2025 · Dec 31, 2025Common Stock (Book)
9.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-738.69MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
256.59MUSDvs all stocks (USD)
52-Week Low
1.69USDUpdated Sep 27, 202652-Week High
5.17USDUpdated Sep 27, 202652-Week Change
33.63%vs all stocks
Beta
2.94xvs all stocks
50-Day MA
3.69USDUpdated Sep 27, 2026200-Day MA
3.10USDUpdated Sep 27, 2026Avg 10-Day Volume
2.15MSharesUpdated Sep 27, 2026Avg 30-Day Volume
2.16MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-0.9100USDUpdated Sep 27, 2026Other Income / Expense
-10.73MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 5.45Altman Z-Score: -0.84
Financial Health
Altman Z-Score -0.84: distress zoneCritical
Altman Z-Score: -0.84
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $35.04M, lower than 95% of all stocks globallySignificant
Revenue (USD): 35,039,000Global P5: 35,820,060.775
Companies that share the same coordination system — how they create, deliver, or capture value.
Shin Poong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Solara Active Pharma Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Sito Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Qinghai Spring Medicinal Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Fennec Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aska Pharmaceutical Holdings Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
NIOX Group plc
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Huasun Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Rezolute, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Palladyne AI Corp
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Xenon Pharmaceuticals Inc.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Hyliion Holdings Corp.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCMulti-Year Debt Decrease With Cash Near Total Debt And Equity